Lipid mediator pathways in the lung: Leukotrienes as a new target for the treatment of asthma

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 5, 1998, Pages 141-146

  Dahlen S E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LORATADINE; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIPID METABOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; STEROID THERAPY;

EID: 0031734819     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.028s5141.x     Document Type: Conference Paper

References (43)

1. Kumlin M. Studies on the metabolism of eicosanoids with respect to their roles in the human lung. Acta Physiol Scand (Suppl) 1991; 596:1-96.
2. 2 on allergen-induced asthma. Am Rev Respir Dis 1993; 148:87-90.
3. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130-7.
4. Holgate ST, Dahlén S-E (eds). From SRS-α to Leukotrienes: the Dawning of a New Treatment in Asthma. Oxford: Blackwell Scientific 1997.
5. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci USA 1979; 76:2148-52.
6. 2 inhibitor which prevents prostaglandin generation. Nature 1979; 278 (5703):456-9.
7. 2. Nature 1997; 390 (6660):622-5.
8. 2 in allergic response and parturition. Nature 1997; 390 (6660):618-22.
9. Manso G, Baker AJ, Taylor IK, Fuller RW. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 1992; 5:712-6.
10. Sebaldt RJ, Sheller JR, Oates JA, Roberts L, JD FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA 1990; 87:6974-8.
11. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149 (4 Part 1):953-9.
12. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147 (6 Part 1):1431-5.
13. Funk CD, Hoshiko S, Matsumoto T, Rdmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 1989; 86:2587-91.
14. Riddick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997; 246:112-8.
15. Tamaoki J, Kondo M, Sakai N et al., The Tokyo Joshi-Idai Asthma Res Group. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155:1235-40.
16. 1 receptor antagonist: correlations with patient's baseline characteristics. Eur Resp J 1997; 10 (Suppl. 25):419.
17. Noonan MJ, Chervinsky P, Brandon M et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998; 11:1232-9.
18. Dahlén B, Nizankowska E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157 (4 Part 1):1187-94.
19. 4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997; 155:1247-53.
20. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
21. Dahlén B, Margolskee DJ, Zetterstrom O, Dahlén S.-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects [see Comments]. Thorax 1993; 48:1205-10.
22. 4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146:96-103.
23. 4 in bronchial asthma. Eur Respir J 1992; 5:693-9.
24. 4, methacholine, and histamine. Am Rev Respir Dis 1990; 142:1112-8.
25. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834-46.
26. Pedersen S, Warner J, Price J. Early use of inhaled steroids in children with asthma (debate). Clin Exp Allergy 1997; 27:995-1006.
27. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94:187-226.
28. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci USA 1980; 77:3710-4.
29. Schild HO, Hawkins DF, Mongar JL, Herxheimer H. Reactions of isolated human asthmatic lung and bronchial trissue to a specific antigen. Lancet 1951; ii:376-82.
30. Brocklehurst WE. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylaxis. J Physiol 1960; 151:416-35.
31. 4. Proc Natl Acad Sci USA 1983; 1712:80-6..
32. Björck T, Dahlén S.-E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol 1993; 6:87-96.
33. Hay DW, Muccitelli RM, Tucker SS et al. Pharmacologic profile of SK & F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 1987; 243:474-81.
34. Jones TR, Charette L, Denis D. Leukotriene and anti-IgE induced contractions of human isolated trachea: studies with leukotriene receptor antagonists and a novel 5-lipoxygenase inhibitor. Can J Physiol Pharmacol 1988; 66:762-8.
35. Wikström-Jonsson E, Dahlén S-E. Interactions between leukotrienes and histamine in the anaphylactic contraction of the guinea pig lung strip. J Pharm Exp Ther 1994; 271:615-23.
36. Roquet A, Dahlén B, Kumlin M et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155:1856-63.
37. 4-receptor antagonist [see Comments]. N Engl J Med 1990; 323:1736-9.
38. Israel E, Dermarkarian R, Rosenberg M et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-4.
39. Dahlén B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterström O, Dahlén S-E. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6:1018-26.
40. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993 148 (6 Part; 1):1447-51.
41. O'Sullivan S, Roquet A, Dahlén B et al. Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur Respir J 1998; 12:345-50.
42. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98:421-32.
43. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151:1734-9.